Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (759)	10/30/2003 2:48:18 PM
From: nigel bates	Read Replies (1) \| Respond to of 2240

I'm familiar with the Arthurian legends. Maybe they have the inside line on the holy grail ?

To: Icebrg who wrote (759)	11/4/2003 3:16:24 AM
From: Icebrg	Read Replies (1) \| Respond to of 2240

Kerry Segal Appointed Vice President, Business Development, at IDM [Going from Cephalon to IDM. On the day when the CIMA acquisition was announced. What gives? Either he fell out completely with Baldino or IDM has some very interesting prospects. But in that case - where?] PARIS--(BUSINESS WIRE)--Nov. 4, 2003--IDM (Immuno-Designed Molecules), a biopharmaceutical company specialized in the field of cellular immunotherapy, announces that Kerry N. Segal has joined the company as Vice President, Business Development. Mr. Segal will be based in Irvine, Calif., where IDM U.S. operations are located. Mr. Segal is a senior professional in business development, licensing and acquisitions, and brings to IDM approximately 20 years of diverse industry experience in pharmaceutical and biotechnology companies. Prior to joining IDM, Mr. Segal held the position of Director, Licensing and Acquisitions, at Cephalon, Inc. since 1998. In this position, he was responsible for global licensing, negotiation of agreements and corporate merger/acquisition strategy. Previously, Mr. Segal worked at several companies in the U.S., including Novartis, Johnson & Johnson, Sandoz Pharmaceuticals, Elkins-Sinn Pharmaceuticals and Bristol Labs Pharmaceutical in various positions in business development, sales and marketing. Mr. Segal holds an MBA from Temple University. "We are delighted to welcome Kerry Segal. His expertise in large biotech and pharmaceutical companies will be a critical asset for IDM's development while we continue to search for new international partnerships," said Jean-Loup Romet-Lemonne, President and CEO.